Brilian

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brilian

What is Brilian? Overview and Quick Facts

Property Description
Active ingredient Gabapentin
Form Oral tablet, oral capsule, oral solution
Pharmacological class Anticonvulsant (Gabapentinoid)
Rx Status Prescription-only medication (Rx-only)
Origin Synthetic neurotransmitter analogue

Understanding Brilian: Definition and Classification

Brilian is the trade name for a prescription-only medication whose active chemical substance is Gabapentin. It is primarily classified as an anticonvulsant (anti-epileptic medication) and belongs to the distinct chemical class of Gabapentinoids. Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Gabapentin is a completely synthetic compound, a nonprotein amino acid developed in a laboratory, ensuring a consistent pharmaceutical substance for stabilizing the Central Nervous System.

Active Composition and General Purpose

The medication is a single-ingredient product available for oral administration in several high-level pharmaceutical preparations, including an oral tablet, an oral capsule, and an oral solution. The active compound, Gabapentin (C9H17NO2), is designed to modulate nerve function. This mechanism is clinically recognized for achieving neurological stabilization by reducing the release of excitatory neurotransmitters.

General Purpose: What Brilian is Designed to Do

The general therapeutic goal of Brilian is addressing nerve hyperexcitability. The drug's capacity to calm disorganized electrical signals makes it suitable for managing conditions where the nervous system is overactive. This action helps to dampen chronic abnormal nerve sensations and prevent uncontrolled neuronal discharge, restoring equilibrium to overstimulated neural pathways.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Brilian?

Official Safety Profile of Brilian (Gabapentin)

The safety profile of Brilian, which contains the active ingredient Gabapentin, is based on classifications published by regulatory authorities. Adverse reactions are grouped by frequency and the body system affected, providing a structured view of the medicine’s risk profile.


Frequency-Classified Adverse Reactions

The most frequently documented effects often involve the Nervous System.

  • Very Common (occurring in 1 in 10 or more people): These typically include Somnolence (sleepiness), Dizziness, and Ataxia (impaired coordination).
  • Common (occurring in less than 1 in 10 people): Reactions such as Fatigue, Weight Increase, Peripheral Edema (swelling), Nausea, Vomiting, Tremor, and Headache are classified as common.

Serious Adverse Reactions

Official labeling documents the potential for rare but clinically significant adverse reactions. These include the risk of Suicidal Thoughts or Behavior, a concern associated with anticonvulsant medications. Severe systemic reactions are also noted, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and serious skin conditions like Stevens-Johnson Syndrome (SJS).


Population-Specific and Contextual Safety Notes

Regulatory safety information notes specific concerns for certain groups. The pediatric population may experience a higher frequency of adverse effects categorized as Psychiatric Disorders, such as hostility and emotional lability. For older adults and those with Renal Impairment, a higher incidence of common effects like dizziness and ataxia is documented due to changes in the drug's clearance. Official warnings also highlight the high safety risk of respiratory depression when Gabapentin is used concurrently with opioids, and the potential for withdrawal seizures upon rapid discontinuation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Brilian carries the primary risk of exaggerating its pharmacological effect, leading to an increased potential for bleeding. Regulatory documents indicate that bleeding is the most significant anticipated clinical factor in an overdose scenario.

Documented Overdose Presentations

Clinical evidence from regulatory filings describes that an overdose may be associated with the following manifestations:

  • Bleeding (increased incidence and severity)
  • Ventricular pauses (abnormal heart rhythm)
  • Gastrointestinal symptoms, including nausea, vomiting, and diarrhoea

High single doses, such as 1,260 mg, have been observed to increase the incidence of both bleeding events and ventricular pauses. The principal risk remains the exacerbation of bleeding.

Required Emergency Actions

In the event of a suspected or confirmed overdose, symptomatic and supportive treatment must be initiated immediately. This care includes continuous ECG monitoring to assess for cardiac abnormalities, such as ventricular pauses. Because Brilian is highly protein-bound, established regulatory information states that dialysis is not expected to be an effective measure for removing the drug from the body. Therefore, management focuses exclusively on addressing the symptoms and providing supportive care, with particular attention to controlling bleeding if it occurs.

Therapeutic Uses of Brilian

What Brilian treats: main uses and benefits

Brilinta (ticagrelor) is an antiplatelet agent primarily used in therapeutic domains related to cardiovascular health. It is commonly used to help manage symptoms related to physical discomfort and heightened physiological activity in patients presenting with conditions characterized by periods of heightened symptoms, specifically those with acute coronary syndrome (ACS). It may assist in reducing the likelihood of certain acute cardiovascular events, such as myocardial infarction (MI, or heart attack) and stroke.

Brilinta is also relevant for easing the overall symptom load for patients with coronary artery disease (CAD), and it may be applied in addressing symptoms linked to acute ischemic stroke or high-risk transient ischemic attack (TIA). Through its intended action, the medication supports patients during difficult episodes and contributes to improved comfort during symptomatic periods. The drug is indicated for a range of conditions, including Acute Coronary Syndrome, patients with a history of Myocardial Infarction, and patients with acute Ischemic Stroke or high-risk Transient Ischemic Attack.

Quick Fact: Used for managing symptoms that interfere with daily functioning

“Provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.”

Eligibility and Restrictions for Use

Eligibility for Brilian

Brilian is established for use in adult patients (18 years and older) who meet the criteria for labeled cardiovascular conditions, such as following Acute Coronary Syndrome (ACS) or a history of Myocardial Infarction (MI).


Absolute Contraindications (Must Not Use)

The medicine is strictly prohibited for use in patients with:

  • A History of Intracranial Hemorrhage.
  • Active Pathological Bleeding (e.g., peptic ulcer).
  • Confirmed Severe Hepatic Impairment.
  • Known Hypersensitivity to the active substance or any component.

Age and Conditional Restrictions

Eligibility is defined by life stage and specific health conditions. Safety and efficacy have not been established in pediatric patients (under 18 years of age). For lactating women, use is not recommended. Furthermore, the medicine must not be initiated in patients scheduled for Urgent Coronary Artery Bypass Graft (CABG) surgery. Use should be considered with caution in patients with Moderate Hepatic Impairment and those at risk of Bradyarrhythmias.

What should I know about interactions with other medicines?

The official regulatory documents establish specific restrictions and requirements for co-administering Brilian (Ticagrelor) with other medicines and substances. These constraints primarily involve drug metabolism via the Cytochrome P450 (CYP) system and the P-glycoprotein (P-gp) transporter, as well as pharmacodynamic interactions.

Contraindicated or Avoided Combinations

  • Strong CYP3A Inhibitors: The co-administration of Brilian must be avoided with medicines that are strong inhibitors of the CYP3A enzyme, such as certain azole antifungals (e.g., ketoconazole, itraconazole) and HIV protease inhibitors (e.g., ritonavir, atazanavir). These agents substantially increase the concentration of Brilian in the body.
  • Strong CYP3A Inducers: The co-administration of Brilian must also be avoided with strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine), as these agents substantially reduce Brilian's concentration and effectiveness.
  • Aspirin Dose: Maintenance doses of Aspirin (acetylsalicylic acid) above 100 mg daily reduce the effectiveness of Brilian and should be avoided.

Required Dose Limitations and Monitoring

  • Simvastatin and Lovastatin: Brilian increases the concentration of statins metabolized by CYP3A4. The dose of Simvastatin or Lovastatin must not exceed 40 mg per day.
  • Digoxin: Because Brilian inhibits the P-gp transporter, Digoxin levels must be monitored upon initiation or change in Brilian therapy.
  • Other Antiplatelet/Anticoagulant Agents: Concomitant use with other agents that affect blood clotting, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or oral anticoagulants, is associated with an increased risk of bleeding.

Mechanism of Action

Brilian's mechanism is driven by its action on the S100B protein, a calcium-binding protein involved in cellular signaling within the central nervous system (CNS). The active component, an anti-S100B antibody, acts as a functional modulator, binding to the S100B protein to regulate its function when its activity is elevated.

This targeted molecular interaction initiates a mechanistic cascade that modifies early signaling steps, influencing pathways governing neurotransmitter homeostasis—the balance between excitatory and inhibitory chemical signals. By normalizing S100B activity, the drug influences this signaling balance, leading to a physiological dampening of excessive signal transmission and stabilization of CNS excitability.

Furthermore, the mechanism reduces the impact of dysregulated neuroinflammatory signaling by minimizing S100B’s potential to act as a cellular stress signal. This targeted pathway interference minimizes S100B-mediated pro-inflammatory signaling, which contributes to the regulation of systemic physiological responsiveness.

Dosage and Administration Information

The medicine Brilinta is administered orally as a film-coated tablet, available in 90 mg and 60 mg strengths. Therapy initiates with a single 180 mg loading dose to achieve the necessary therapeutic levels. The official dosing regimen proceeds with a standardized twice-daily (BID) schedule. For the first year of treatment, the required maintenance dose is 90 mg twice daily. For extended, long-term use following the initial year, the dose is adjusted downward to 60 mg twice daily.

Administration is flexible regarding meal timing, as the tablets may be taken with or without food. A key procedural constraint is the necessary co-administration with a maintenance dose of aspirin (ASA). This daily aspirin dose must be kept within the range of 75 mg to 100 mg, as daily doses exceeding 100 mg are known to impair the drug's effectiveness. Tablets can be crushed to a fine powder and mixed with water for patients who require administration via an oral or nasogastric tube (size CH8 or greater).

Regarding specific populations, no dose modification is necessary for older adults or for patients with renal impairment, but use is avoided in severe hepatic impairment. If a scheduled dose is missed, patients should take only the next dose at the scheduled time; missed doses should never be doubled.

Recent Clinical Evidence

Evidence for Acute Coronary Syndrome (ACS)

Clinical research for Brilian in people who have recently experienced a heart attack or severe chest pain, conditions known as Acute Coronary Syndrome (ACS), was primarily conducted through large-scale, international Randomized Controlled Trials (RCTs). These studies was studied for a short to intermediate time interval, comparing a regimen of Brilian plus aspirin against a specific comparator antiplatelet treatment plus aspirin. Researchers examined outcomes related to systemic or functional imbalance, specifically looking at the time until a patient experienced a Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke.

Major studies reported measurements of how often these composite outcomes occurred in the patient groups. The findings describe patterns observed when comparing the two active treatments. The research also closely examined outcomes related to severe bleeding events, which was observed in some studies to increase when using prescribed antiplatelet medicines.

However, the follow-up durations were limited in these pivotal trials, meaning long-term effects are not fully established beyond the initial 12 months. Scientific literature also explores the varied scientific interpretations of the initial trial data.

Evidence for Secondary Event Prevention After a Heart Attack

Brilian was evaluated in a second set of large, long-term Randomized Controlled Trials focused on people who had already experienced a heart attack one to three years prior and were considered to have ongoing risk factors. The long-term RCTs examined outcomes related to episodic or acute changes over a longer period, up to three years, specifically looking at the cumulative occurrence of CV Death, MI, or Stroke.

Over the observation period, the trials reported how symptoms evolved in the observed populations and described a pattern where the overall frequency of the composite endpoint was lower in the groups receiving Brilian compared to the placebo group. The data also showed patterns where an increased frequency of both major and minor bleeding events was observed in the Brilian groups. It is important to note that the reported effect on all-cause or CV death alone was not statistically distinguished from the placebo group in these long-term studies.

Frequently Asked Questions (FAQ)

Common questions about Brilian (FAQ)

Q: What happens when you stop taking Brilian suddenly?

Official labeling advises against stopping Brilian abruptly. Because the body can develop physical dependence on the medication, sudden cessation may trigger withdrawal symptoms, including an increased risk of seizures. When discontinuation is necessary, regulatory documents state that the medication is typically tapered to reduce the risk of withdrawal symptoms.


Q: Does Brilian interact with common over-the-counter pain relievers?

Regulatory information indicates Brilian is not known to interact with common pain relievers like acetaminophen or ibuprofen. However, Brilian can be affected by certain over-the-counter antacids that contain aluminum or magnesium. To prevent these antacids from reducing the medication's effectiveness, a time separation is typically required when taking the medication alongside these antacids.


Q: Does drinking alcohol affect how Brilian works?

Yes, regulatory information warns that consuming alcohol while taking Brilian can intensify certain side effects. Since both alcohol and Brilian affect the Central Nervous System (CNS), combining them may increase the risk of side effects such as dizziness, drowsiness, and difficulty concentrating, and may heighten the risk of severe effects like respiratory depression.


Q: Does Brilian have any known long-term side effects?

Official labeling documents adverse reactions based on clinical studies and post-marketing reports. The labeling documents potential serious reactions, such as suicidal thoughts or behaviors, which are monitored throughout the course of treatment, but it does not separate long-term effects from effects observed during intermediate treatment duration.


Q: Is it safe to drive or operate machinery while taking Brilian?

Official warnings caution that the medication may impair a patient's ability to drive or operate complex machinery due to side effects such as somnolence (sleepiness) and dizziness. Patients are advised to assess how the medication affects them before engaging in such activities.


Q: Does Brilian interact with common vitamins or supplements?

Official drug labeling primarily focuses on interactions with other prescription drugs and antacids. There are no specific warnings regarding common vitamins. Patients are encouraged to review all supplements and vitamins with a healthcare professional to check for potential interactions.


Q: Are there any dietary restrictions I need to follow while on Brilian?

There are no general dietary restrictions associated with taking Brilian. The only necessary restriction noted in regulatory documents involves the use of certain antacids. A time separation is typically required when taking the medication alongside aluminum- or magnesium-containing antacids to prevent reduced effectiveness.


Q: Can women who are planning to conceive take Brilian?

Regulatory documents indicate that no adequate studies have been conducted on Brilian's use in pregnant women. Decisions regarding its use in women planning to conceive should be based on a careful assessment of the risks and benefits, as is standard for all anticonvulsant medications.


Q: Why is Brilian considered a [Drug Class]?

Brilian's active ingredient is classified as an anticonvulsant (also known as an anti-epileptic drug) because of its mechanism of action. It works by binding to a specific site on nerve cells to reduce the release of certain excitatory chemical signals. This action helps to stabilize nerve activity.


Q: Is it common to feel dizzy or lightheaded on Brilian?

Yes, official safety information states that dizziness is a Very Common adverse reaction, affecting 1 in 10 people or more. Lightheadedness is a related symptom that is also commonly reported in clinical trial and post-marketing data.


Q: What happens if a child accidentally takes Brilian?

Official labeling requires all medications to be kept out of the reach of children. If a child accidentally takes Brilian, official guidance recommends immediately seeking advice from a Poison Control Center. Symptoms of an overdose may include severe dizziness, impaired coordination, and slowed or shallow breathing.


Q: Is there a possibility of becoming dependent on Brilian?

Yes, official labeling notes that Brilian has the potential for causing physical dependence. This means that the body may adapt to the drug’s presence and rely on it to maintain normal function. This is the reason why the dose must be tapered when discontinuation is being considered.


Q: What is the difference between Brilian and generic versions?

Brilian is the brand name for the active ingredient Gabapentin. The generic version contains the same active medicinal substance, strength, and form. According to regulatory agencies, generic versions must meet the same strict quality and performance standards as the brand name drug.


Q: Is there a preferred time of day to take Brilian?

The drug is typically prescribed multiple times a day. While the schedule should be consistent, official information allows for the timing to be adjusted to help manage common side effects. For instance, a dose may be taken at bedtime to potentially mitigate the effects of drowsiness.


Q: Are there any known allergic reactions to Brilian?

Yes, official safety information documents the potential for serious, life-threatening allergic reactions, including anaphylaxis (a severe, systemic reaction) and angioedema (swelling). The label also notes the risk of severe skin conditions such as Stevens-Johnson Syndrome (SJS) and DRESS.


Q: How does Brilian specifically target the condition it treats?

Brilian's mechanism involves interacting with a specific nerve component to reduce the release of excitatory neurotransmitters. This action is thought to calm overstimulated nerve signaling, which is the physiological basis for its therapeutic effect in both seizure prevention and the management of certain types of nerve pain.


Q: How quickly should I expect to feel the effects of Brilian?

Regulatory data shows the drug is rapidly absorbed, reaching peak levels in the bloodstream within 2 to 3 hours after administration. However, the time it takes to notice the full therapeutic effect on symptoms can vary widely among patients and may require several weeks of consistent use.


Q: Why do some people say Brilian makes them feel tired?

The medication's effect on the Central Nervous System (CNS) is the reason for this common side effect. Official labeling states that Somnolence (sleepiness) and Fatigue are common to very common adverse reactions, as they are direct consequences of the drug's activity in calming the central nervous pathways.


Q: Can Brilian cause weight changes?

Yes, official safety data indicates that Weight Increase is listed as a common adverse reaction in people taking Brilian. This is a recognized side effect that is documented in the official labeling for the drug.


Q: Is it normal to have mild headaches when first starting Brilian?

Yes, Headache is listed as a common adverse reaction. Regulatory information notes that many adverse effects, including headache, are often more noticeable when a patient first begins treatment.


Q: What kind of monitoring (blood tests, etc.) is needed while on Brilian?

While routine blood tests are generally not required for the drug itself, official guidance advises that patients be monitored closely for the development of serious side effects. This includes monitoring for signs of suicidal thoughts or behavior, severe allergic reactions like DRESS, and respiratory depression.


Q: Does Brilian affect sleep patterns?

Brilian can affect sleep patterns in several ways. The official adverse reaction list includes both somnolence (sleepiness) and fatigue as common effects. Conversely, some official labeling also lists insomnia (difficulty falling or staying asleep) as a common side effect.


Q: Does Brilian affect blood sugar levels?

Although changes in blood sugar are not listed as a common side effect, regulatory information notes that post-marketing reports have indicated instances of blood glucose fluctuations and hypoglycemia (low blood sugar), particularly in diabetic patients.


Q: How long does Brilian stay in your system after stopping it?

The time it takes for a drug to be cleared from the body is based on its elimination half-life. For Brilian in an adult with normal kidney function, the half-life is typically 5 to 7 hours. Complete clearance takes several half-lives and is longer for patients who have impaired kidney function.

How should Brilian be stored and disposed of?

How to Store and Dispose of Brilian? (Gabapentin)

Brilian (Gabapentin) must be stored according to official regulatory requirements to ensure product stability.

Storage Conditions

The medication must be kept at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). The solid forms (tablets and capsules) must be stored in the original container and kept tightly closed to protect them. The Gabapentin oral solution must not be frozen and, if dispensed in liquid form, must be discarded after 6 months from the date of dispensing or opening.

Handling and Disposal

Gabapentin and all medicines must be kept out of the sight and reach of children. Unused or expired medication should be disposed of according to official state or local regulations, typically through a drug take-back program. The oral solution should not be disposed of in the drain or toilet unless specifically authorized by official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brilian found in:

A-Z Index: